These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Planning and monitoring of equivalence studies. Durrleman S; Simon R Biometrics; 1990 Jun; 46(2):329-36. PubMed ID: 2194579 [TBL] [Abstract][Full Text] [Related]
3. A comparison of adaptive allocation rules for group-sequential binary response clinical trials. Morgan CC; Stephen Coad D Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177 [TBL] [Abstract][Full Text] [Related]
4. Frequentist evaluation of group sequential clinical trial designs. Emerson SS; Kittelson JM; Gillen DL Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678 [TBL] [Abstract][Full Text] [Related]
5. Study duration for clinical trials with survival response and early stopping rule. Kim K; Tsiatis AA Biometrics; 1990 Mar; 46(1):81-92. PubMed ID: 2350572 [TBL] [Abstract][Full Text] [Related]
6. Exact significance testing to establish treatment equivalence with ordered categorical data. Mehta CR; Patel NR; Tsiatis AA Biometrics; 1984 Sep; 40(3):819-25. PubMed ID: 6518249 [TBL] [Abstract][Full Text] [Related]
7. Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach. Emerson SS Biometrics; 1995 Sep; 51(3):1152-62. PubMed ID: 7548699 [TBL] [Abstract][Full Text] [Related]
8. Implementing type I & type II error spending for two-sided group sequential designs. Rudser KD; Emerson SS Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592 [TBL] [Abstract][Full Text] [Related]
10. [Methodological and statistical aspects of equivalence and non inferiority trials]. Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296 [TBL] [Abstract][Full Text] [Related]
11. Issues in the use of adaptive clinical trial designs. Emerson SS Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553 [TBL] [Abstract][Full Text] [Related]
12. Some issues in the design and interpretation of 'negative' clinical studies. Makuch RW; Johnson MF Arch Intern Med; 1986 May; 146(5):986-9. PubMed ID: 3963987 [TBL] [Abstract][Full Text] [Related]
13. Group sequential design and analysis of clinical equivalence assessment for generic nonsystematic drug products. Tsong Y; Zhang JJ; Wang SJ J Biopharm Stat; 2004 May; 14(2):359-73. PubMed ID: 15206533 [TBL] [Abstract][Full Text] [Related]
14. Designs for group sequential phase II clinical trials. Chang MN; Therneau TM; Wieand HS; Cha SS Biometrics; 1987 Dec; 43(4):865-74. PubMed ID: 3427171 [TBL] [Abstract][Full Text] [Related]
15. A sequential test for comparing two infection rates in a randomized clinical trial, and incorporation of data accumulated after stopping. Samuel-Cahn E; Wax Y Biometrics; 1986 Mar; 42(1):90-108. PubMed ID: 3719066 [TBL] [Abstract][Full Text] [Related]
16. Sequential equivalence testing and repeated confidence intervals, with applications to normal and binary responses. Jennison C; Turnbull BW Biometrics; 1993 Mar; 49(1):31-43. PubMed ID: 8513110 [TBL] [Abstract][Full Text] [Related]
17. [The importance of equivalence trials in showing the usefulness of treatments]. Hermens ML; van Hout HP; Terluin B; Adèr HJ; de Haan M Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2162-6. PubMed ID: 14626832 [TBL] [Abstract][Full Text] [Related]
18. Group sequential clinical trials with triangular continuation regions. Whitehead J; Stratton I Biometrics; 1983 Mar; 39(1):227-36. PubMed ID: 6871351 [TBL] [Abstract][Full Text] [Related]
19. Sequential design approaches for bioequivalence studies with crossover designs. Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740 [TBL] [Abstract][Full Text] [Related]